InflaRx NV (InflaRx NV) EV-to-Revenue : -375.81 (As of May. 10, 2024)

View and export this data going back to 2017. Start your Free Trial

What is InflaRx NV EV-to-Revenue?

EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, InflaRx NV's enterprise value is $-25.18 Mil. InflaRx NV's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 was $0.07 Mil. Therefore, InflaRx NV's EV-to-Revenue for today is -375.81.

The historical rank and industry rank for InflaRx NV's EV-to-Revenue or its related term are showing as below:

IFRX' s EV-to-Revenue Range Over the Past 10 Years
Min: -705.52 Med: -126.55 Max: 499.32
Current: -375.81

During the past 9 years, the highest EV-to-Revenue of InflaRx NV was 499.32. The lowest was -705.52. And the median was -126.55.

IFRX's EV-to-Revenue is ranked better than
99.52% of 1038 companies
in the Biotechnology industry
Industry Median: 8.305 vs IFRX: -375.81

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

As of today (2024-05-10), InflaRx NV's stock price is $1.20. InflaRx NV's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was $0.00. Therefore, InflaRx NV's PS Ratio for today is 1,200.00.

InflaRx NV EV-to-Revenue Historical Data

The historical data trend for InflaRx NV's EV-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

InflaRx NV EV-to-Revenue Chart

InflaRx NV Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EV-to-Revenue

Get a 7-Day Free Trial

-18.00

InflaRx NV Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
EV-to-Revenue	Get a 7-Day Free Trial															-	-	-	834.51	-18.00

Competitive Comparison of InflaRx NV's EV-to-Revenue

For the Biotechnology subindustry, InflaRx NV's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

InflaRx NV's EV-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, InflaRx NV's EV-to-Revenue distribution charts can be found below:

* The bar in red indicates where InflaRx NV's EV-to-Revenue falls into.

InflaRx NV EV-to-Revenue Calculation

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

InflaRx NV's EV-to-Revenue for today is calculated as:

EV-to-Revenue	=	Enterprise Value (Today)	/	Revenue (TTM)
	=	-25.179	/	0.067
	=	-375.81

InflaRx NV's current Enterprise Value is $-25.18 Mil.
InflaRx NV's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.07 Mil.

InflaRx NV (NAS:IFRX) EV-to-Revenue Explanation

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

InflaRx NV's PS Ratiofor today is calculated as:

PS Ratio	=	Share Price (Today)	/	Revenue per Share (TTM)
	=	1.20	/	0.001
	=	1,200.00

InflaRx NV's share price for today is $1.20.
InflaRx NV's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00.

InflaRx NV EV-to-Revenue Related Terms

Thank you for viewing the detailed overview of InflaRx NV's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

InflaRx NV (InflaRx NV) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » InflaRx NV (NAS:IFRX) » Definitions » EV-to-Revenue

Comparable Companies

Traded in Other Exchanges

IF0:Germany IF0:Germany

Address

Winzerlaer Strasse 2, Jena, DEU, 07745

Website

https://www.inflarx.de

InflaRx NV is a clinical-stage biopharmaceutical company focused on applying proprietary anti-C5a/C5aR technology to discover and develop first-in-class, potent and specific inhibitors of the complement activation factor known as C5a and its receptor known as C5aR. C5a is an inflammatory mediator involved in the progression of a wide variety of autoimmune and other inflammatory diseases. Its lead product candidate, vilobelimab, is a novel intravenously delivered first-in-class anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings.